ClinicalTrials.gg
CompletedNCT04045405Updated Jan 9, 2026

Clinical Study to Assess Safety, PK and PD Parameters of CDR132L

A Phase 1 interventional study of CDR132L in Heart Failure, sponsored by Cardior Pharmaceuticals GmbH. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Cardior Pharmaceuticals GmbH (part of Novo Nordisk A/S) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Heart Failure by Novo Nordisk A/S — 5 open to participants now, 6 under way, 2 of them phase 3. Heart Failure · Novo Nordisk A/S.

Enrollment
10th of 11
28 · median 200
Started
2019
the only one that year
Phase 1
4 of 14
2 open now
Registered
1st of 14
by date

Among the 14 studies in Heart Failure by Novo Nordisk A/S, this one is the 10th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2019, is one of 4 in phase 1, and was the 1st registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 14 studies in Heart Failure by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Heart Failure by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This is a Phase I, randomized, double-blind, placebo-controlled study to assess safety, pharmacokinetics and pharmacodynamic parameters of CDR132L in patients with stable heart failure of ischemic origin (NYHA 1-3).

Read the detailed description

Objectives:

Primary

  • To assess the safety of one single and one repeated dose of CDR132L in patients with stable heart failure of ischemic origin (NYHA 1-3).

Secondary • To characterize the pharmacokinetic (PK) profile of CDR132L in patients with stable heart failure of ischemic origin.

Exploratory

  • To determine the effect of CDR132L on pharmacodynamic (PD) parameters.
03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stable heart failure of ischemic origin

Exclusion criteria

Exclusion Criteria:

  • Heart failure of non-ischemic origin (hypertensive heart disease, myocarditis, alcoholic cardiomyopathy and cardiac dysfunction due to rapid atrial fibrillation),
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    CDR132L

    Drug: CDR132L

  • Placebo comparator
    Saline

    Drug: CDR132L

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events [safety and tolerability]

    The incidence and severity of treatment-emergent adverse events (TEAEs)

    Time frame: 4 months

Secondary outcomes

  1. Maximum plasma concentration (Cmax)

    Pharmacokinetics parameter derived by non-compartmental methods to measure maximum observed plasma concentration (Cmax)

    Time frame: 4 months

  2. Time to reach maximum plasma concentration (Tmax)

    Pharmacokinetics parameter derived by non-compartmental methods to measure time to maximum plasma concentration (Tmax)

    Time frame: 4 months

  3. Area under the curve (AUC0-t)

    Pharmacokinetics parameter area under the plasma concentration-time curve from time zero to last detectable plasma concentration (AUC0-t)

    Time frame: 4 months

  4. Area under the curve (AUC0-inf)

    Pharmacokinetics parameter area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-inf)

    Time frame: 4 months

  5. Blood clearance (CL)

    Pharmacokinetics parameter to determin clearance considering terminal elimination rate

    Time frame: 4 months

  6. Half life (t1/2)

    Pharmacokinetics parameter to determin half-life rate (t1/2)

    Time frame: 4 months

  7. Volume of distribution (Vdss)

    Pharmacokinetics parameter

    Time frame: 4 months

07

Study locations

1 site
  • Richmond Pharmacology Ltd., 1A Newcomen Street, London Bridge
    London, SE1 1YR, United Kingdom
08

References and documents

Publications

  • Taubel J, Hauke W, Rump S, Viereck J, Batkai S, Poetzsch J, Rode L, Weigt H, Genschel C, Lorch U, Theek C, Levin AA, Bauersachs J, Solomon SD, Thum T. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. Eur Heart J. 2021 Jan 7;42(2):178-188. doi: 10.1093/eurheartj/ehaa898. PubMed 33245749 ↗
  • Huang CK, Kafert-Kasting S, Thum T. Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease. Circ Res. 2020 Feb 28;126(5):663-678. doi: 10.1161/CIRCRESAHA.119.315856. Epub 2020 Feb 27. PubMed 32105576 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Jan 2020, 7 months.

Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 7 months is close to that.

Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2019
First posted
Aug 5, 2019
StartActual
Jun 21, 2019
Primary completionActual
Jan 31, 2020
CompletionActual
Jun 26, 2020
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04045405
Responsible party
Sponsor
First posted
Aug 5, 2019
Start date
Jun 21, 2019
Primary completion
Jan 31, 2020
Completion
Jun 26, 2020
Last update
Jan 9, 2026

Study contacts

Wilfried Hauke, MD MFPM
study director · Cardior Pharmaceuticals GmbH CMO
Jorg Taubel, MD FFPM
principal investigator · Richmond Pharmacology Ltd CEO

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CDR132L

Start the discussion